We are live on ! Find out more
ATXS

Astria Therapeutics
ATXS

Delisted

ATXS was delisted on the 22nd of January, 2026.

Back to rankings

103 hedge funds and large institutions have $622M invested in Astria Therapeutics in 2024 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 33 increasing their positions, 38 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

36% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 11

23% more capital invested

Capital invested by funds: $506M → $622M (+$116M)

3% more funds holding

Funds holding: 100 → 103 (+3)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

1.07% less ownership

Funds ownership: 101.22% → 100.15% (-1.1%)

13% less repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 38

37% less call options, than puts

Call options by funds: $482K | Put options by funds: $769K

Holders
103
Holders Change
+3
Holders Change %
+3%
% of All Funds
1.48%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
15
Increased
33
Reduced
38
Closed
11
Calls
$482K
Puts
$769K
Net Calls
-$287K
Net Calls Change
+$75K

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$19.7M
2
VPC
Vestal Point Capital
New York
+$8.34M
3
Millennium Management
Millennium Management
New York
+$7.16M
4
RG
Redmile Group
California
+$3.46M
5
Invesco
Invesco
Georgia
+$3.34M

Top Sellers

Rank Fund Capital Flow
1
VC
Vivo Capital
California
-$8.63M
2
Citadel Advisors
Citadel Advisors
Florida
-$6.93M
3
State Street
State Street
Massachusetts
-$5.51M
4
AAA
Affinity Asset Advisors
New York
-$2.79M
5
CSS
Cubist Systematic Strategies
Connecticut
-$2.56M
Name Holding Trade Value Shares
Change 		Change in
Stake
Goldman Sachs
26
Goldman Sachs
New York
$2.99M -$1.37M -123,303 -31%
DCM
27
DAFNA Capital Management
California
$2.8M -$222K -20,000 -7%
Morgan Stanley
28
Morgan Stanley
New York
$2.53M +$1.32M +119,051 +108%
Walleye Capital
29
Walleye Capital
New York
$1.92M +$767K +68,939 +65%
Wellington Management Group
30
Wellington Management Group
Massachusetts
$1.62M +$131K +11,763 +9%
SFM
31
Sphera Funds Management
Israel
$1.5M -$292K -26,260 -16%
UOC
32
UBS O'Connor
Illinois
$1.37M +$128K +11,537 +10%
Bank of New York Mellon
33
Bank of New York Mellon
New York
$1.3M -$235K -21,136 -15%
N
34
Nuveen
North Carolina
$1.14M -$2.16M -194,520 -65%
TCM
35
Tang Capital Management
California
$1.1M – – –
ACM
36
ADAR1 Capital Management
Texas
$1.03M -$499K -44,874 -32%
Barclays
37
Barclays
United Kingdom
$1.02M +$426K +38,321 +71%
SI
38
Sofinnova Investments
California
$943K +$277K +24,948 +41%
Bank of America
39
Bank of America
North Carolina
$899K -$537K -48,301 -37%
SSA
40
Schonfeld Strategic Advisors
New York
$872K +$881K +79,205 New
CAM
41
ClariVest Asset Management
California
$731K – – –
RhumbLine Advisers
42
RhumbLine Advisers
Massachusetts
$669K -$51.1K -4,593 -7%
UBS Group
43
UBS Group
Switzerland
$662K -$62.1K -5,589 -9%
Swiss National Bank
44
Swiss National Bank
Switzerland
$648K +$655K +58,900 New
SC
45
Stempoint Capital
New York
$619K +$626K +56,287 New
UBS AM
46
UBS AM
Illinois
$613K +$619K +55,696 New
AllianceBernstein
47
AllianceBernstein
Tennessee
$595K – – –
Rafferty Asset Management
48
Rafferty Asset Management
New York
$588K -$628K -56,445 -51%
PSC
49
Patient Square Capital
California
$434K +$438K +39,422 New
JP Morgan Chase
50
JP Morgan Chase
New York
$431K +$219K +19,735 +102%
1
2
3 4 5

ATXS Hedge Fund Activity: Q3 2024 in Review

103 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Astria Therapeutics (ATXS) for Q3 2024, worth a combined $622M — up 23% from $506M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new ATXS positions and 11 closed out — a net gain of 4 holders — while 33 added to existing stakes and 38 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $19.7M. The largest seller was Vivo Capital, cutting an estimated $8.63M.

  • 103 institutional investors held Astria Therapeutics (ATXS) as of Q3 2024, up from 100 in Q2 2024.
  • Funds reported $622M of Astria Therapeutics stock for Q3 2024, up 23% quarter-over-quarter.
  • 15 funds opened new Astria Therapeutics positions in Q3 2024 and 11 closed out, a net change of +4 holders.
  • The largest Astria Therapeutics buyer in Q3 2024 was Fidelity Investments, an estimated $19.7M added.
  • The largest Astria Therapeutics seller in Q3 2024 was Vivo Capital, an estimated $8.63M sold.

Based on aggregated 13F filings for Q3 2024.